Emergent Gets $1.6 Bln Worth Long Term Contract To Develop, Deliver NuThrax

(RTTNews) - Emergent BioSolutions Inc. (EBS) Friday announced a multi-year contract with the Biomedical Advanced Research and Development Authority for the advanced development and delivery of NuThrax or AV7909, the company's next generation anthrax vaccine candidate. The five year contract is valued at up to $1.6 billion.

The contract is to develop NuThrax for post-exposure prophylaxis of anthrax disease and to deliver to the Strategic National Stockpile an initial two million doses following Emergency Use Authorization pre-approval by the U.S. Food and Drug Administration

The contract also includes procurement options for the delivery of an additional 7.5 million to 50 million doses of NuThrax to the SNS, valued from approximately $255 million to up to $1.4 billion,

The authority is a division of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response.